Ipsen
Resilient Triumph: Roche and Exelixis’ Tecentriq-Cabometyx Combination Shows Promise in Advanced Prostate Cancer After Past Challenges
Anika Sharma
After facing setbacks in clinical trials, the combination of Roche’s Tecentriq and Exelixis’ Cabometyx has achieved a breakthrough in treating ...
FDA Grants Approval to Ipsen’s Sohonos Capsules, the First-Ever Treatment for Individuals with Fibrodysplasia Ossificans Progressiva
Anika Sharma
In 2019, Ipsen made a significant investment of $1 billion to acquire Clementia Pharmaceuticals and its rare disease drug, palovarotene. ...
